Metagenomi Therapeutics, Inc. (MGX)

Metagenomi Therapeutics, Inc. (MGX) is a healthcare company (biotechnology) based in the United States. The share price is $0.63, down 7.21% on the day, which values the company at $23.86M. Price as of 18 Nov 2026, 08:38 UTC, from Yahoo Finance.

Key facts

Share price
$0.63−7.21% today
Market value
$23.86M
Funk Score
36/100
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Metagenomi Therapeutics, Inc. in more detail

MGX trades at -0.3× next year's expected earnings, 3.4× sales.

Its Funk Score is 36 out of 100 (financial strength 3.8, profitability 0.0, growth 6.9, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

Metagenomi Therapeutics, Inc. (MGX): questions and answers

What is Metagenomi Therapeutics, Inc.'s market cap?

Metagenomi Therapeutics, Inc. is valued at $23.86M at a share price of $0.63.

How fast is Metagenomi Therapeutics, Inc. growing?

Over the last three fiscal years Metagenomi Therapeutics, Inc.'s revenue grew 13.6% a year.

Does MGX pay a dividend?

Metagenomi Therapeutics, Inc. does not currently pay a regular dividend.

Cite this page

Funkfolio, “Metagenomi Therapeutics, Inc. (MGX) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/MGX

Underlying data: Yahoo Finance; company filings with the SEC.